W. E. Donoghue & Co. LLC Takes Position in Johnson & Johnson (JNJ)

W. E. Donoghue & Co. LLC acquired a new position in shares of Johnson & Johnson (NYSE:JNJ) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 121,854 shares of the company’s stock, valued at approximately $16,120,000. Johnson & Johnson comprises 1.8% of W. E. Donoghue & Co. LLC’s investment portfolio, making the stock its 23rd biggest holding.

A number of other hedge funds have also bought and sold shares of JNJ. State Street Corp increased its holdings in Johnson & Johnson by 4.3% during the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after purchasing an additional 6,656,371 shares during the last quarter. BlackRock Inc. increased its holdings in Johnson & Johnson by 2.6% during the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after purchasing an additional 4,332,612 shares during the last quarter. Janus Henderson Group PLC increased its holdings in Johnson & Johnson by 717.9% during the 2nd quarter. Janus Henderson Group PLC now owns 3,748,008 shares of the company’s stock worth $495,837,000 after purchasing an additional 3,289,763 shares during the last quarter. Vanguard Group Inc. increased its holdings in Johnson & Johnson by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after purchasing an additional 3,023,110 shares during the last quarter. Finally, Parametric Portfolio Associates LLC increased its holdings in Johnson & Johnson by 47.9% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 7,970,670 shares of the company’s stock worth $1,054,433,000 after purchasing an additional 2,581,562 shares during the last quarter. Institutional investors own 65.89% of the company’s stock.

Several research analysts have recently commented on JNJ shares. Cowen reiterated an “outperform” rating and issued a $155.00 target price (up previously from $147.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. UBS reiterated a “buy” rating and issued a $148.00 target price on shares of Johnson & Johnson in a research report on Thursday, August 31st. Jefferies Group lifted their target price on Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, October 16th. Zacks Investment Research upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Finally, Credit Suisse Group set a $154.00 target price on Johnson & Johnson and gave the stock an “outperform” rating in a research report on Thursday, October 19th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $145.04.

Johnson & Johnson (NYSE JNJ) opened at $142.46 on Monday. Johnson & Johnson has a 12-month low of $110.76 and a 12-month high of $144.35. The stock has a market capitalization of $382,721.66, a P/E ratio of 19.95, a P/E/G ratio of 2.90 and a beta of 0.80. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The business had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. During the same quarter in the previous year, the firm posted $1.68 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. equities analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th were given a dividend of $0.84 per share. The ex-dividend date was Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a yield of 2.36%. Johnson & Johnson’s dividend payout ratio is currently 58.33%.

ILLEGAL ACTIVITY NOTICE: “W. E. Donoghue & Co. LLC Takes Position in Johnson & Johnson (JNJ)” was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/12/18/w-e-donoghue-co-llc-takes-position-in-johnson-johnson-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

What are top analysts saying about Johnson & Johnson? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Johnson & Johnson and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit